Endomorphin-1
Endogenous Opioid PeptideAlso known as: YPWF-NH2
A tetrapeptide with the highest selectivity & affinity for the mu-opioid receptor of any known endogenous opioid. Research tool for understanding mu-receptor-mediated analgesia.
Typical Dose
Research standard
Route
Intrathecal or IV (research)
Cycle
N/A
Half-life
<1 minute in plasma
Storage
Lyophilized: −20°C.
Overview
Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) was identified in 1997 as the most selective & potent endogenous mu-opioid receptor agonist known. It produces analgesia, hypothermia, & catalepsy in animal models. Unlike beta-endorphin, it lacks significant delta-opioid activity. Stable analogs are under development for pain management. Not for clinical or research self-administration.
Quick Start Guide
Research reference compound only.
Research Indications
Mu-opioid receptor research
Research OnlyHighest selectivity endogenous MOR agonist. Standard research tool.
Side Effects & Safety
When to Stop
- Signs of opioid toxicity
How to Reconstitute
Research reconstitution.
Dosing math: Research use only.
Quality Indicators
Good — use as normal
- Clear solution
Discard immediately
- Particulate
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample